Browse the evidence

GH improves exercise capacity in GHD through increased oxygen delivery (cardiac output, blood volume) and substrate availability (fat oxidation), not primarily through increased muscle strength.

GH replacement works by improving how your heart pumps blood and how your body burns fat during exercise, rather than just building bigger muscles.

Adiponectin (APN) exerts cardiovascular protective effects by activating AMPK and eNOS pathways, promoting endothelial cell survival, reducing inflammation, and inhibiting atherosclerosis progression.

Maintaining healthy adiponectin levels is crucial for heart health. Since adiponectin levels drop in obesity and diabetes, focusing on reducing visceral fat and improving insulin sensitivity through diet and exercise can help restore these protective hormonal signals. While direct supplementation is not currently standard clinical practice due to production complexities, lifestyle interventions that mimic APN's effects (like exercise-induced AMPK activation) are beneficial.

Obesity and high glucose/high lipid environments induce 'APN resistance' by disrupting the AdipoR1/caveolin signalosome, thereby diminishing the cardioprotective effects of adiponectin.

If you have diabetes or obesity, your body may become resistant to the protective effects of adiponectin. This 'APN resistance' means that simply having the hormone isn't enough; the signaling pathway is broken. Addressing the underlying metabolic stress (glucose/lipid control) is necessary to restore this protective signaling.

Sarcolemmal localization of C18:0 ceramide and specific sphingomyelin species is inversely related to insulin sensitivity in human skeletal muscle, whereas sarcolemmal 1,2-DAGs are not significantly related.

Focus on improving insulin sensitivity through exercise and metabolic health rather than just obsessing over total body fat or muscle fat content. The location and type of lipids matter more than the total amount. Endurance training appears to alter lipid localization in a way that preserves insulin sensitivity despite higher total lipid levels.

Chronic glucocorticoid exposure simultaneously activates triglyceride synthesis and lipolysis in inguinal adipose tissue, maintaining neutral fat storage levels while increasing metabolic turnover.

Chronic stress or elevated cortisol levels trigger a complex response in belly fat (inguinal fat) where the body simultaneously builds up and breaks down triglycerides. This high turnover can contribute to metabolic issues like insulin resistance without necessarily causing immediate, visible weight gain. Managing stress is crucial not just for weight, but for the metabolic health of fat tissue.

Chronic administration of the GLP-1 receptor agonist liraglutide leads to desensitization of its gastric emptying (GE) inhibitory effects, whereas its body weight-lowering effects persist without desensitization.

Long-acting GLP-1 medications like liraglutide work by changing how your brain regulates appetite, not by keeping food in your stomach. While you might feel nausea or slowed digestion initially, your body adapts to this GI effect, but the weight loss continues because the brain's hunger signals remain suppressed. This suggests the medication is effective for sustained weight management even after side effects subside.

The central nervous system (CNS) integrates peripheral adiposity signals (insulin and leptin) and gastrointestinal signals (GLP-1) to regulate both energy balance and glucose homeostasis through overlapping hypothalamic mechanisms.

Your brain acts as a command center for metabolism, listening to hormones like insulin and leptin to decide how to store or burn energy. If these signals are ignored or misinterpreted by the brain (CNS dysfunction), it can lead to obesity and type 2 diabetes, regardless of peripheral efforts.

Hypothalamic AMPK and mTOR act as fuel sensors that integrate energy status signals to regulate food intake and energy expenditure.

Your brain uses molecular sensors (AMPK and mTOR) to detect energy availability. When these sensors are activated or inhibited by nutrients or hormones, they adjust your hunger and energy expenditure.

Beta-adrenergic blockade via propranolol significantly reduces glucose-induced thermogenesis (GIT) in healthy humans, indicating that approximately 30% of the thermogenic response to glucose is mediated by the sympathetic nervous system.

Your body uses your sympathetic nervous system to burn extra calories when you eat, specifically in response to carbohydrates. This 'thermic effect' is not just the mechanical cost of storing food; about 30% of it is an active, regulated process driven by adrenaline-like signals. Blocking this pathway (e.g., with beta-blockers) reduces your ability to burn these excess calories, potentially contributing to weight gain or making weight loss harder.

Nuclear translocation of Perilipin 5, triggered by catecholamine-induced PKA phosphorylation, integrates lipid droplet lipolysis with mitochondrial biogenesis by forming transcriptional complexes with PGC-1α and SIRT1 to promote fatty acid catabolism.

This research explains how your body coordinates fat burning with energy production during stress or fasting. When you engage in activities that trigger adrenaline (like exercise or fasting), your body doesn't just burn fat; it simultaneously builds the mitochondrial machinery to handle that fat. This suggests that combining metabolic stressors (like fasting with exercise) may optimize metabolic efficiency by leveraging this natural coordination mechanism.

Higher maternal intake of protein and fat during pregnancy is associated with higher offspring intake of the same nutrients at age 10, suggesting in utero programming of appetite.

Maternal nutrition during pregnancy, specifically protein and fat intake, appears to influence the child's appetite and food preferences later in life. While this does not mean parents should restrict these nutrients, it suggests that a balanced, nutrient-dense diet during pregnancy may help establish healthier eating patterns in the child.

Menopause increases the risk and severity of OSA in women due to the loss of protective hormonal effects (progesterone) and changes in fat distribution.

If you are postmenopausal and experiencing new sleep issues, snoring, or fatigue, ask about sleep apnea. The protective effect of female hormones decreases after menopause, significantly increasing your risk. It is not just 'part of aging' and is treatable.

Aging is associated with reduced SIRT1 activity, which leads to decreased pVHL levels and subsequent stabilization of HIF-1α, resulting in impaired mitochondrial biogenesis and functional decline.

As you age, your body's ability to regulate oxygen-sensing pathways (specifically the SIRT1-pVHL-HIF-1α axis) changes, leading to reduced mitochondrial efficiency. While you cannot directly 'dose' this mechanism, understanding that this is a natural part of aging helps contextualize fatigue and metabolic changes. Interventions like caloric restriction or compounds like resveratrol are mentioned as potential ways to support SIRT1 activity, but the primary takeaway is that this is a complex, multi-factorial biological process.

Intermittent hypoxia (such as from Obstructive Sleep Apnea) activates NFκB and inflammatory mediators like TNF-α without sufficiently stabilizing HIF-1α, leading to chronic inflammation and disease progression.

If you have Obstructive Sleep Apnea (OSA), the intermittent drops in oxygen do not trigger the protective HIF-1α response seen in sustained hypoxia. Instead, they trigger inflammation (NFκB/TNF-α), which accelerates aging and disease. Treating OSA (e.g., with CPAP) is crucial to reducing this inflammatory burden.

Activation of AMPK during hypoxia and aging promotes mitochondrial biogenesis via PGC-1α and inhibits chronic inflammation by suppressing NFκB, thereby extending healthspan.

Activating AMPK (through exercise, caloric restriction, or compounds like metformin) supports mitochondrial health and reduces chronic inflammation. This is a key mechanism for extending healthspan and preventing age-related diseases.

Exposure to environmental obesogens (e.g., tributyltin, BPA, phthalates) increases susceptibility to obesity by altering developmental programming of stem cells and metabolic regulation, independent of caloric intake.

Minimize exposure to known obesogens like BPA (plastics), phthalates, and organotins (marine contaminants, PVC pipes). Use glass or stainless steel containers, avoid heating food in plastic, and choose fresh over processed foods to reduce intake of additives and packaging leachates, especially during pregnancy and early childhood.

Genetic susceptibility to common obesity is distributed across a mosaic of specific neuronal cell types in the brain (including hypothalamus, midbrain, and cortex) rather than being driven by a single canonical energy homeostasis circuit.

This research suggests that obesity is not caused by a single broken part in the brain but involves a complex network of neurons across multiple regions. This implies that treatments targeting only one area (like the hypothalamus) might be insufficient for everyone, and future therapies may need to address this broader neural network.

Fetal malnutrition (low birth weight) combined with postnatal caloric abundance causes irreversible metabolic programming (thrifty phenotype) that predisposes individuals to insulin resistance and obesity in adulthood.

If you were born small or experienced early childhood malnutrition, your body may be biologically programmed to store fat aggressively when food is abundant. Focus on environmental controls (food availability) and early childhood nutrition rather than relying solely on adult willpower.

Tribulus Terrestris supplementation does not improve muscle strength, body composition, or testosterone levels in trained individuals, despite marketing claims to the contrary.

Do not take Tribulus Terrestris expecting it to increase your testosterone or muscle strength. Research shows it has no effect on these metrics in trained individuals. It is likely a waste of money, though it may have a placebo effect.

In obese, insulin-resistant individuals, skeletal muscle mitochondria exhibit increased reactive oxygen species (ROS) production and lower abundance of Complex I subunits and CPT1B protein, despite maintaining normal maximal mitochondrial respiration rates.

For obese, insulin-resistant individuals, the problem isn't that your mitochondria can't burn fat (maximal capacity is normal), but that they are leaking harmful ROS and have lower levels of key fat-burning entry proteins (CPT1B). This suggests focusing on strategies that reduce oxidative stress and improve mitochondrial efficiency rather than just 'boosting capacity'.

Rapamycin has symptomatic, aging-independent effects on cognitive function and motor activity in mice, improving performance in young and old animals alike.

Rapamycin may improve cognitive and motor function in mice regardless of age, suggesting symptomatic benefits. However, this does not equate to slowing aging. Human application for cognitive enhancement remains experimental and carries immunosuppression risks.

Low free testosterone levels predict increased mortality from cardiovascular disease (CVD) in older men, whereas low testosterone is not associated with mortality from other causes.

For older men, low free testosterone is a specific warning sign for heart-related death risk, not necessarily for all causes of death. While this suggests checking hormone levels might help assess cardiovascular risk, it does not support using testosterone therapy as a general anti-aging or longevity treatment. Focus on cardiovascular health markers rather than assuming low T alone dictates lifespan.

Insulin promotes protein anabolism by inducing the transcription factor ATF4, which activates genes for amino acid uptake and synthesis, while glucocorticoids inhibit this pathway by repressing ATF4.

This research highlights that muscle building (anabolism) is actively regulated by hormones. Insulin promotes muscle growth by turning on specific genetic programs (ATF4) for amino acid handling, while stress hormones (glucocorticoids) shut these programs down. For practical application, this suggests that chronic stress or high cortisol levels can directly inhibit the molecular machinery required for muscle protein synthesis, independent of protein intake.

Diverting bile flow to the distal small intestine (ileum) produces weight loss and metabolic improvements comparable to Roux-en-Y gastric bypass (RYGB) surgery.

This research suggests that the metabolic benefits of bariatric surgery (like RYGB) are largely driven by how bile acids are delivered to the intestine, specifically the ileum. While this specific surgical procedure (GB-IL) is not a standard clinical option yet, it highlights that manipulating bile acid signaling could be a key target for future non-surgical or less invasive treatments for obesity and type 2 diabetes. For now, standard bariatric surgery remains the most effective surgical option, but understanding this mechanism may lead to new drugs or simpler procedures.